Relapsed/Refractory Follicular Lymphoma Conundrums

Slides:

Advertisements

Similar presentations

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Advertisements

State of the Art in BRCA-Mutated Ovarian Cancer

New Horizons for SMA.

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Evolving Paradigms in the Management of HR-Positive Breast Cancer

Applying Biosimilars in Hematologic Cancers

Unraveling Clinical Developments in NASH

Improving Survival in Glioblastoma Multiforme

Advances in Managing Inhibitors in Patients With Hemophilia A

Progression After Cancer Immunotherapy in Advanced NSCLC

New Standards of Care in ALK-Translocated Advanced NSCLC

Atopic Dermatitis Treatment Landscape

Prolonging Progression-Free Survival in Follicular Lymphoma

Mid-Year Hemophilia Update

Atopic Dermatitis Treatment Landscape

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

PARP Inhibitors and Cancer: What Do You Need to Know?

Treating Transplant-Ineligible Patients With Multiple Myeloma

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Nurse View.

The Evolving Role of Immunotherapy in NSCLC

Treatment Decisions in Chemorefractory Follicular Lymphoma

Individualizing Care in Ovarian Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma

Navigating New Oral Treatment Algorithms in CLL

Targeting BTK Signaling in B-Cell Malignancies

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Optimizing Outcomes and Managing Adverse Events in CLL

Immunotherapy for cSCC

Novel Approaches in T1D Management

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

New Data on Emerging Treatments for Psoriasis

How to Select Therapy In Newly Diagnosed CLL

Personalizing Management in the Care of Patients With Advanced Sarcoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Parkinson Disease Psychosis

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced Lung Cancer

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Patient Questions and Expert Answers in Psoriasis:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Psychiatrist's Role in Tardive Dyskinesia

FDA-Approved PI3K Inhibitors for CLL and FL

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Novel Concepts in the Management of RCC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.

From Adjuvant to Metastatic in Melanoma

The Psychiatrist's Role in Tardive Dyskinesia

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Checkpoint Inhibitors in First-Line Advanced NSCLC

How to Select Therapy in Relapsed/Refractory CLL

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Changing Paradigms in Relapsed/Refractory Indolent NHL

Presentation transcript:

Relapsed/Refractory Follicular Lymphoma Conundrums

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Epidemiology of FL

Presentation Topics

Recommended Frontline Therapies for FL

Considerations in Selecting Therapy for R/R FL

Recommended Second-Line Therapies for FL

Management Challenges in R/R FL

Strategies for Selecting Therapy for R/R FL

Novel Therapies

Copanlisib

CHRONOS-1 Trial of Copanlisib Methods

CHRONOS-1 Trial of Copanlisib Efficacy

CHRONOS-1 Trial of Copanlisib Safety

Idelalisib

Phase 2 Trial of Idelalisib Monotherapy in R/R FL Design and Efficacy

Phase 2 Trial of Idelalisib Monotherapy in R/R FL Safety

Duvelisib

DYNAMO Trial of Duvelisib

MAGNIFY Trial of Rituximab + Lenalidomide Design

MAGNIFY Trial Response

MAGNIFY Trial PFS

MAGNIFY Trial Safety

Additional Trials of R + Lenalidomide

Obinutuzumab

GADOLIN Trial Design

GADOLIN Trial Efficacy

GADOLIN Trial Safety

Incorporating New Agents Into Treatment Paradigm Challenges

Incorporating New Agents Into Treatment Paradigm Selection

Current Knowledge About Novel Agents

Ongoing Trials in R/R FL

Abbreviations

Abbreviations (cont)